Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06714071

Relation of C-reactive Protein/ Albumin Ratio and Coagulation Profile in Acute Myeloid Leukemia Patients

The investigators will investigate the relation between CAR and coagulation profile in newly diagnosed AMl patients

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

AML

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Assiut University

Asyut, Egypt

About this study

Acute myeloid leukaemia (AML) is an aggressive haematological malignancy with a high degree of heterogeneity. It has long been recognized that systemic inflammation is associated with tumorigenesis it revealed that elevated C-reactive protein levels were associated with worse survival outcomes in patients with various types of cancer, including hematologic malignancies. Serum albumin is a measure of an individual's nutritional status. Systemic inflammation can reduce serum albumin concentrations by increasing capillary permeability . The ratio of CRP to albumin (CAR) is a useful score based on inflammation and nutrition, reflecting not only systemic inflammation status but also nutritional status. The Glasgow prognostic score (GPS) and modified GPS (mGPS), determined by the serum CRP and albumin levels, have been proposed as prognostic indicators for AML patients. However, the clinical correlations of CAR and its prognostic value in AML patients have not yet been clarified. Abnormalities of hemostasis can occur in leukemia in the form of disseminated intravascular coagulation(DIC), coagulation protein defect and primary fibrinolysis . Clinically, Types of acute myeloid leukemia like acute promyelocyticleukemia has a high frequency of haemorrhage due to disseminated intravascular coagulation (DIC), which contributes to the high mortality rate of this disease . Therefore, the investigators will investigate CAR its relation with inflammatory response and coagulation profile levels in newly diagnosed acute myeloid leukemia and after 3 month follow up to compare their level and the relation between .

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all cases newly diagnosed with acute myeloid leukemiain assuit university hospital

Exclusion criteria

  • cases with chronic myeloid leukemia
  • cases with acute lymphoblasticleukemia

Treatment and study plan

CRP and Albumin and coagulation profile

Diagnostic Test

CRP and Albumin and coagulation profile

Primary outcomes

  1. Correlation between C- reactive protein and coagulation profile in AML patients

    Time frame: Study complete an average 2 years

    the investigators will investigate the correlation between CAR and coagulation profile in newly diagnosed AMl patients by measure crp and coagulation profile in newly diagnosed patient and up to 3 month follow up

Study contacts

Contact information is provided by the study sponsor or research team.

hebatallah addellatif, prof

CONTACT

[email protected]

01006829911

shrouk mosallam, master

CONTACT

[email protected]

01014396113

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 3, 2024
Registry last updated
Jan 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.